Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib

Journal of Clinical Pharmacology

Volumn 53, Issue 12, 2013, Pages 1261-1267

  Prieto Pérez, Rocío ^a   Ochoa, Dolores ^a   Cabaleiro, Teresa ^a   Román, Manuel ^a   Sánchez Rojas, Sergio Daniel ^a   Talegón, María ^a   Abad Santos, Francisco ^a,b  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Celecoxib; CYP2C8; CYP2C9; Pharmacogenetics; Pharmacokinetics

Indexed keywords

CELECOXIB; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; YOUNG ADULT;

CELECOXIB; CYP2C8; CYP2C9; PHARMACOGENETICS; PHARMACOKINETICS;

ADULT; ARYL HYDROCARBON HYDROXYLASES; CROSS-OVER STUDIES; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, GENETIC; PYRAZOLES; SULFONAMIDES; YOUNG ADULT;

EID: 84893003464     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.169     Document Type: Article

References (31)

1. Clemett D, Goa KL. Celecoxib: A review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs. 2000;59:957-980. [Pubmed: 10804043].
2. Paulson SK, Hribar JD, Liu NW, et al. Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers. Drug Metab Dispos. 2000;28:308-314. [Pubmed: 10681375].
3. Tang C, Shou M, Mei Q, Rushmore TH, Rodrigues AD. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenaseII inhibitor. J Pharmacol Exp Ther. 2000;293:453-459. [Pubmed: 10773015].
4. Sandberg M, Yasar U, Stromberg P, Hoog JO, Eliasson E. Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br J Clin Pharmacol. 2002;54:423-429. [Pubmed: 12392591].
5. FDA (Food and Drugs Administration). US Department of Health and Human Services. Center for Drug Evaluation and Research (CDER). Clinical Pharmacology and Biopharmaceutics Review of celecoxib (Celebrex® capsules). NDA: 20998. Available at: Http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008 4344b1-07-06-Celebrex%20Label.pdf
6. Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib: A selective cyclooxygenase2 inhibitor. Clin Pharmacokinet. 2000;38:225- 242. [Pubmed: 10749518].
7. HapMap web page. Available at: Http://hapmap.ncbi.nlm.nih.gov/cgiperl/ gbrowse/hapmap28-B36/. Accessed January 28, 2013.
8. Dai D, Zeldin DC, Blaisdell JA, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics. 2001;11:597-607. [Pubmed: 11668219].
9. Yasar U, Lundgren S, Eliasson E, et al. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun. 2002;299:25-28. [Pubmed: 12435384].
10. Speed WC, Soonmo PK, Tuck DP, Lyndsay NH, Kidd KK. Global variation in CYP2C8CYP2C9 functional haplotypes. Pharmacogenomics J. 2009;9:283-290. [Pubmed: 19381162].
11. Cabaleiro T, Román M, Ochoa D, et al. Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. Drug Metab Dispos. 2013;41:224-229. [Pubmed: 23118328].
12. Agundez JA, GarciaMartin E, Martínez C. Genetically based impairment in CYP2C8 and CYP2C9dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: Is a combination of pharmacogenomics and metabolomics required to improve personalized medicine Expert Opin Drug Metab Toxicol. 2009;5:607- 620. [Pubmed: 19422321].
13. Kirchheiner J, Stormer E, Meisel C, Steinbach N, Roots I, Brockmoller J. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics. 2003;13:473-480. [Pubmed: 12893985].
14. Brenner SS, Herrlinger C, Dilger K, et al. Influence of age and cytochrome P450 2C9 genotype on the steadystate disposition of diclofenac and celecoxib. Clin Pharmacokinet. 2003;42:283-292. [Pubmed: 12603175].
15. De Finetti program. Available at: Http://ihg2.helmholtzmuenchen. de/cgibin/hw/hwa1.pl
16. Solé X, Guinó E, Valls J, Iniesta R, Moreno V. SNPStats: A web tool for the analysis of association studies. Bioinformatics (Oxford, England). 2006;22:21263-22265. [Pubmed: 16720584].
17. SNPStats web page. http://bioinfo.iconcologia.net/SNPstats
18. Fries S, Grosser T, Price TS, et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase2. Gastroenterology. 2006;130:55-64. [Pubmed: 16401468].
19. Cavallari LH, Jeong H, Bress A. Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmgenomics Pers Med. 2011;4:4123-4136. [Pubmed: 23226058].
20. Gong L, Thorn CF, Bertagnolli MM, Grosser T, Altman RB, Klein TE. Celecoxib pathways: Pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012;22:310-318. [Pubmed: 22336956].
21. Chan AT, Zauber AG, Hsu M, et al. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology. 2009;136:2127-2136; e2121. [Pubmed: 19233181].
22. Stempak D, Bukaveckas BL, Linder M, Koren G, Baruchel S. Cytochrome P450 2C9 genotype: Impact on celecoxib safety and pharmacokinetics in a pediatric patient. Clin Pharmacol Ther. 2005;78:309-310. [Pubmed: 16153401].
23. Tang C, Shou M, Rushmore TH, et al. Invitro metabolism of celecoxib, a cyclooxygenase2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: Correlation with CYP2C9 genotype and invivo pharmacokinetics. Pharmacogenetics 2001 11:223-235. [Pubmed: 11337938].
24. Werner U, Werner D, Pahl A, Mundkowski R, Gillich M, Brune K. Investigation of the pharmacokinetics of celecoxib by liquid chromatographymass spectrometry. Biomed Chromatogr. 2002 16:56-60. [Pubmed: 11816012].
25. Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005;77:1-16. [Pubmed: 15637526].
26. Miners JO, Birkett DJ. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. Br J Clin Pharmacol. 1998;45:525-538. [Pubmed: 9663807].
27. Shon JH, Yoon YR, Kim KA, et al. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics. 2002;12:111-119. [Pubmed: 11875365].
28. Lundblad MS, Ohlsson S, Johansson P, Lafoile P, Eliasson E. Accumulation of celecoxib with a 7fold higher drug exposure in individuals homozygous for CYP2C9-3. Clin Pharmacol Ther. 2006;79:287-288. [Pubmed: 16513453].
29. Bahadur N, Leathart JB, Mutch E, et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alphahydroxylase activity in human liver microsomes. Biochem Pharmacol. 2002;64:1579-1589. [Pubmed: 12429347].
30. Hruska MW, Frye RF, Langaee TY. Pyrosequencing method for genotyping cytochrome P450 CYP2C8 and CYP2C9 enzymes. Clin Chem. 2004;50:2392-2395. [Pubmed: 15563491].
31. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) - Ficha técnica. Available at: Http://www.aemps.gob.es/cima/especialidad. dometodoverFichaWordPdf&codigo63073 &formatopdf& formularioFICHAS&fileficha.pd. Revised: December 2012.